

## ISOPP CAPHO Symposium 2025 Summary

It was a pleasure to have attended ISOPP CAPHO 2025 last weekend and an honor to have been chosen at a top 4 presenting abstract. It was a weekend filled with meeting esteemed professionals in the industry from coast-to-coast and internationally.

The conference kicked off with a lunch symposium sponsored by J&J titled “Latest learning and Best Practices for the Implementation of Bispecific Antibodies for Multiple Myeloma in the Community.” I was particularly excited to attend this session as I have worked for 1 year in multiple myeloma at a small, start-up size pharmaceutical company. The session was a great overview of best practices when it comes to managing cytokine release syndrome (CRS) and iCANS, two major concerns associated with administering bispecific antibodies J&J has developed for multiple myeloma. One particular clinical pearl that stood out to me was the importance of wearing a medical bracelet to ensure that if admitted to the emergency department, symptoms such as fever, hypotension, and hypoxia would get urgently treated rather than left waiting for hours to prevent end organ toxicity. Still, after collecting poll answers surveying the comfort level of bispecific antibodies in specialized oncology centers, it seemed that education still poses as a significant barrier to familiarity and ease of use.

Another standpoint session for me was the session titled “Considerations of Indigenous Care in Pharmacy Practice.” I greatly appreciated that ISOPP CAPHO as a whole shed light on so many international cultural considerations including indigenous populations. It was very enlightening to learn that there are Traditional Healing clinics in locations such as Alaska to respect and honour patients’ choice to consider other treatment modalities for their cancer journey. In addition, I greatly appreciated the sharing of models of practice during the Q&A session of this symposium.

The rest of the symposium comprised of informative sessions on using molecular sequencing to guide treatment decisions, dose banding in oncology practice, as well as round table discussions and presentations on current innovative practices being completed by oncology pharmacists across the world.

I left the conference feeling particularly hopeful and enthralled for the future of improved and tailored patient care in oncology practice. Another omnipresent theme that I heard throughout many sessions was the influx of patients at cancer centres and the lack of funding. This is where I am hopeful that with the uptake and announcement of more subcutaneous oncology regimens, more and more patients will be seen with the available resources that we have in clinics. I am incredibly grateful to have attended CAPHO on

behalf of the travel grant and have had the opportunity to share my research demonstrating the cost differences between biosimilar IV and SC oncology regimens.